Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cosiporfin sodium, also known as DVDMS or Sinoporphyrin sodium, is a small molecule photosensitizer used in photodynamic therapy (PDT). It is a sodium salt of an ether-linked porphyrin dimer. When administered and subsequently activated by light of a specific wavelength (typically 630 nm), cosiporfin sodium generates reactive oxygen species (ROS), primarily singlet oxygen. These ROS induce oxidative damage, leading to tumor cell death through mitochondrial-dependent and extrinsic apoptotic pathways. It preferentially accumulates in tumor cells and has been shown to inhibit the expression of proliferating cell nuclear antigen (PCNA) and Bcl-xL, while increasing cleaved caspase-3 levels. Additionally, it contributes to vascular obstruction within cancerous tissues. Cosiporfin sodium is being investigated for its antineoplastic effects, particularly in advanced esophageal cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cosiporfin sodium.